Metabolize announced USD 3.2 million in seed financing on 15 October 2026, led by Astanor. Founded by Dr Morris Laster and Gideon Meir, the San Francisco company is commercializing licensed research originating at Stanford Medicine. Its Precision Metabolite Technology focuses on naturally occurring compounds with defined biological roles. The capital will support product development, validation, manufacturing and commercialization. Maia Ventures, LongGame Venture and SOSV also participated. Metabolize plans to introduce its first consumer product, NATLEAN, in January 2027, targeting people transitioning off GLP-1 therapies. That intended use is a development objective, not evidence that the product has established clinical effectiveness.
Metabolize raises USD 3.2m to develop metabolic health products
Astanor leads seed financing for the San Francisco company

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


